The PSL Alliance

Biocleave’s aim is to make biological reagents accessible to pioneering life science researchers. To achieve this they have moved away from traditional protein expression technologies, and have established a brand-new recombinant protein expression host, capable of overcoming many of the limitations inherent in E. coli and eukaryotic systems. By combining the benefits of commercially proven, non-pathogenic, clostridial microbes with their world-leading genome engineering technologies, Biocleave are increasing the availability of previously difficult-to-express proteins. A further advantage afforded by their system – the proteins supplied by Biocleave are naturally endotoxin free.

Biocleave’s core market is research use only (RUO) proteins, for the study of multiple cellular activities such as cell signalling, replication, transcription, and translation. Their proprietary technology, coupled with the unique characteristics of clostridia, enable them to overcome the typical protein expression challenges of production host toxicity and costly development cycles.